Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Banco Vida Corp.
WARNING LETTER
•Banco Vida Corp.•September 18, 2019

Banco Vida Corp. – FDA Warning Letter, Sep 18, 2019

Record Details

The FDA issued a Warning Letter to Banco Vida Corporation and Laboratorio Banco Vida following inspections in September 2019, identifying significant violations related to their manufacture and distribution of human umbilical cord blood (HCT/Ps) and cord blood intermediates. The HCT/Ps are regulated as drugs and biological products because they do not meet the criteria for regulation solely under 21 CFR Part 1271, specifically failing homologous use and metabolic activity requirements (21 CFR 1271.10(a)(2) and (a)(4)). A major violation is the marketing of these unapproved biological products without a valid biologics license application (BLA) or an Investigational New Drug (IND) application in effect (42 U.S.C. 262(a), 21 U.S.C. 355(i)).

Additional significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) were observed. These include failure to screen donors for relevant communicable disease agents like Zika virus (ZIKV) and transmissible spongiform encephalopathy (21 CFR 1271.75(a) and (d)), inadequate procedures to prevent microbiological contamination (e.g., unvalidated aseptic processes, lack of gowning procedures, poor personnel practices), and insufficient written procedures for production and process control (e.g., unvalidated manufacturing, use of R&D/expired reagents, no time limits). Furthermore, the firm lacked adequate cleaning and maintenance procedures for equipment, did not conduct environmental and personnel monitoring, and had inaccurate batch records. The FDA deemed the firm's responses inadequate, emphasizing the significant safety concerns posed by these deficiencies. The firm must promptly correct all violations to avoid further regulatory action.

Company
Banco Vida Corp.
Inspection date
September 18, 2019
Product type
Biologics
Office
Center for Biologics Evaluation and Research
People
  • Elizabeth A. Waltrip (Program Division Director)
  • Amy Graf
View Company Profile

ID · a2bf2f67-4b2d-454a-9e88-0fa2e8413208

Violation Codes10
21 U.S.C. 321(g)21 CFR 1271.3(e)21 CFR 1271.3(d)21 CFR 1271.75(a)(1)21 CFR 1271.75(b)21 CFR 1271.75(c)21 CFR 1271.75(d)21 CFR 1271.3(r)(2)21 CFR 1271.1521 CFR 1271.10(a)

Full citation text and observation details available on the Dashboard.

Other documents for Banco Vida Corp.
  • 483 - 2021-08-12August 12, 2021
  • EIR - 2021-08-12August 12, 2021
  • 483 - 2019-09-18September 18, 2019
  • EIR - 2019-09-18September 18, 2019
  • WARNING_LETTER - 2019-09-18September 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Banco Vida Corp.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.